Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International publ : strengthens its commercial leadership

03/25/2020 | 02:31am EST

 Uppsala, Sweden, March 25, 2020. Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks a significant milestone in the upcoming commercialization of DiviTum[®] on the US market. 

"As DiviTum[®] is approaching commercialization we are strengthening the team. Robert brings insights from cancer diagnostics as well as therapeutics and has an excellent track record of successful product launches which will be valuable when launching DiviTum[®]. The appointment of Robert is an important step in bringing DiviTum[®] to the US market, for the benefit of cancer patients," said Anders Rylander, CEO of Biovica.


Robert Dann has extensive experience in cancer therapeutics, diagnostics and analytics. He previously led life sciences and oncology marketing at IBM Watson Health. He also served in roles leading strategic marketing and oncology marketing at GE Healthcare. Earlier in his career, among other roles, Robert led the global launch of the hit estrogen blocker Faslodex for AstraZeneca and was country general manager in Russia and in Finland. He will start in his role at Biovica on 1 April.


"While great progress has been made in developing new therapies for cancer, there are still sizable gains to be made in better understanding how well a therapy is working during the course of treatment. With pioneering work on cell proliferation markers, Biovica is at the forefront of those improvements. I am excited to be a part of the team," said Robert Dann. "So far, DiviTum[®] has shown great results in clinical studies, and I am confident it can help clinicians make more informed decisions, so patients get the best possible treatment."


For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.




(c) 2020 Cision. All rights reserved., source Press Releases - English

2020BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..
2020BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..
2020BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..
2020BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
2020BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
2020BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
2020Biovica Year-end Report for 2019/2020
2020BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
2020BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..
2020BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..
More news
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,64 M -4,64 M
Net cash 2021 134 M 16,1 M 16,1 M
P/E ratio 2021 -32,2x
Yield 2021 -
Capitalization 1 244 M 150 M 150 M
EV / Sales 2021 370x
EV / Sales 2022 26,0x
Nbr of Employees 21
Free-Float 75,2%
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 44,90 SEK
Spread / Highest target 129%
Spread / Average Target 49,2%
Spread / Lowest Target -31,0%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors